Composition for treating hepatitis C virus, regulating phosphorylation of replicase

Patent metadata

Field	Value
Publication number	US-9249159-B2
Application number	US-201214130107-A
Country	US
Kind code	B2
Filing date	Apr 23, 2012
Priority date	Jun 30, 2011
Publication date	Feb 2, 2016
Grant date	Feb 2, 2016

Abstract

The present invention relates a novel composition for preventing or treating hepatitis C virus, regulating the phosphorylation of a replicase. More specifically, it is possible to prevent or treat hepatitis C using a novel PRK2 inhibitor discovered through structure modeling, and to prevent or treat hepatitis C, particularly, interferon-insensitive hepatitis C through coadministration of an Hsp90 inhibitor.

First claim

What is claimed is:

1. A method for treating hepatitis C virus in a subject in need thereof comprising
administering to said subject a pharmaceutically effective amount of a PRK2 (Protein Kinase C-related Kinase 2) inhibitor,
wherein the PRK2 inhibitor is selected from the group consisting of: 3-[(2-ethylbutanoyl)amino-N-(pyridine-4-yl)benzamide], cyclohexanecarboxylic acid (1H -benzoimidazole-5-yl)-amide, (3r, 5r, 7r)-N-(quinolin-5-yl)adamantane-1-carboxamide, 1-methyl-4-phenylpiperidine-4-carbonitrile), N-(2-oxoazepan-3-yl)pyridine-4-carboxamide), 2-oxo-N-4-pyridinyl-3-piperidinecarboxamide, N-(2-oxoazepan-3-yl)pyridine-4-carboxamide, 2-oxo-N-(pyridine-4-yl)-2H-chromene-3-carboxamide, 2-oxo-N-(4-pyridinyl)-1,2-dihydro-3-pyridinecarboxamide, 1-benzyl-2-oxo-N-(4-pyridinyl)-1,2-dihydro-3-pyridinecarboxamide, and 5-oxo-N-pyridine-4-yl-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxamide.

2. The method for treating hepatitis C virus of claim 1 , wherein the PRK2 inhibitor is administered in combination with an Hsp90 (Heat Shock Protein 90) inhibitor.

3. The method for treating hepatitis C virus of claim 2 , wherein the Hsp90 inhibitor is selected from the group consisting of 17-AAG (17-allyaminogeldanamycin), and 17-DMG (17-(dimethylaminoethylamino)-17-demethoxygeldanamycin).

4. The method for treating hepatitis C virus of claim 1 , wherein the PRK2 inhibitor is administered in combination with the IFN-α.

Assignees

• Oh Jong-Won
• Univ Yonsei Iacf

Inventors

• Oh Jong-Won

Classifications

• C07D401/12

  linked by a chain containing hetero atoms as chain links · CPC title

• A61K31/444

  containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone · CPC title

• C07D235/08

  Radicals containing only hydrogen and carbon atoms · CPC title

• A61K31/7048

  having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin} · CPC title

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title